White Paper
Cell and Gene Therapy Commercialization
Accelerate commercial success with payer, physician and patient buy-in
Mar 09, 2021
Cell and gene therapies (CAGTs) are beginning to provide significant value across multiple therapy areas driven by a combination of their clinical benefit, durability and the overall response rate. Despite this, CAGTs have yet to achieve the anticipated market penetration, with fewer than 20% of patients eligible for Chimeric Antigen Receptor T-cell (CART) therapy in the US receiving it, meaning there is still a significant way to go before all patients who could benefit from these therapies, do benefit.
Contact Us